Brian S. Biesman, M.D.
Specialist
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 94
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: University of Michigan Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
TN license MD30378
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension Saint Thomas Hospital Nashville, TN
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 94
- Services billed
- 3,118
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, incobotulinumtoxin a, 1 unit | 2,390 | 11 |
| Photography of content of eyes | 61 | 59 |
| New patient office or other outpatient visit, 15-29 minutes | 54 | 54 |
| Injection of chemical for paralysis of nerve muscles on side of face | 36 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tramadol Hcl Other prescribers in Nashville, TN | 43 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Nashville, TN | 19 |
| Methylprednisolone Other prescribers in Nashville, TN | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 25 payments worth $94,549 in total to this clinician.
| AbbVie Inc. | $85,074 |
|---|---|
| Revance Therapeutics, Inc. | $6,490 |
| Solta Medical, A Division of Bausch Health US, LLC | $1,900 |
| Botanix Sb Inc | $1,000 |
| Galderma Laboratories, L.P. | $68.19 |
| Merz North America, Inc. | $17.46 |
| Grant | $85,000 |
|---|---|
| Consulting Fee | $7,975 |
| Compensation for services other than consulting (speaking, faculty) | $950 |
| Food and Beverage | $624 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Apr 18, 2025 | Grant | $50,000 |
| AbbVie Inc. Apr 17, 2025 | Grant BOTOX · FACIAL AESTHETICS | $17,500 |
| AbbVie Inc. Mar 25, 2025 | Grant SKYRIZI · IMMUNOLOGY | $15,000 |
| Revance Therapeutics, Inc. Aug 1, 2025 | Consulting Fee DAXXIFY · AESTHETICS AND THERAPEUTICS | $3,625 |
| AbbVie Inc. May 5, 2025 | Grant BOTOX · BOTOX THERAPEUTIC | $2,500 |
| Revance Therapeutics, Inc. Sep 2, 2025 | Consulting Fee DAXXIFY · AESTHETICS AND THERAPEUTICS | $2,400 |
| Botanix Sb Inc May 16, 2025 | Consulting Fee SOFDRA · DERMATOLOGY | $1,000 |
| Solta Medical, A Division of Bausch Health US, LLC May 1, 2025 | Consulting Fee | $950 |
| Solta Medical, A Division of Bausch Health US, LLC Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) | $950 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $125,895 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants
AbbVie Inc. · Completed · NCT06399718 - M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study
AbbVie Inc. - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.